Resources with keywords: ebola
Includes recommendations for clinical and public health labs, clinicians and the public.
Following the confirmation of an outbreak of Sudan virus disease – which belongs to the same family as Ebola virus disease – in Uganda today, World Health Organization (WHO) is mobilizing efforts to support the national health authorities to swiftly contain and end the outbreak.
This guidance refers only to the following viral hemorrhagic fevers: Ebola, Marburg, Lassa, Crimean Congo Hemorrhagic Fever (CCHF), and the South American Hemorrhagic Fevers (i.e., those caused by Junin, Machupo, Chapare, Guanarito and Sabia viruses).
Yang W, et al.
Highlights
- Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein is lethal in immunocompetent Syrian hamsters.
- The pathogenicity of VSV-EBOV/GP is species-specific, age-related, gender-associated, and challenge route-dependent.
- Syrian hamsters develop uveitis, multi-organ failure, and severe systemic diseases resembling symptoms of human EBOV patients.
- The model is available for anti-EBOV antibody and vaccine evaluation under BSL-2 conditions.
Coulborn R, et al
Vaccination with the Ebola vaccine significantly lowered case fatality risk vs not vaccinated.
This guidance applies to viral hemorrhagic fevers caused by infections with:
- Filoviruses (ebolaviruses and marburgviruses),
- Arenaviruses [Lassa, Lujo, and South American hemorrhagic fever viruses (Guanarito virus, Sabia virus,
- Junin virus, Chapare virus, Machupo virus)],
- Rift Valley fever virus, and
- Crimean Congo hemorrhagic fever virus.
WHO declares outbreak in Uganda with a rare Ebola Sudan virus.
